Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
نویسندگان
چکیده
منابع مشابه
Design of the Tocilizumab in Giant Cell Arteritis Trial
Overview. The GiACTA trial is a multicenter, randomized, double-blind, and placebo-controlled study designed to test the ability of tocilizumab (TCZ), an interleukin (IL)-6 receptor antagonist, to maintain disease remission in patients with giant cell arteritis (GCA). Design. Approximately 100 centers will enroll 250 patients with active disease. The trial consists of a 52-week blinded treatmen...
متن کاملLong-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
Giant cell arteritis (GCA) is a chronic systemic vasculitis affecting large-sized and medium-sized vessels. Glucocorticoids are currently the mainstay of treatment for GCA and associated large vessel vasculitis (LVV) but are associated with frequent adverse events. Methotrexate has only demonstrated a modest benefit while anti-TNF biological agents (infliximab and etanercept) have been ineffica...
متن کاملProfile of tocilizumab and its potential in the treatment of giant cell arteritis
Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinica...
متن کاملInfliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
BACKGROUND Tumor necrosis factor-alpha is present in arteries in giant cell arteritis. OBJECTIVE To evaluate the efficacy of infliximab, an anti-tumor necrosis factor-alpha agent, in giant cell arteritis. DESIGN Randomized, controlled trial. SETTING 22 sites in the United States, the United Kingdom, Belgium, Italy, and Spain. PATIENTS 44 patients with newly diagnosed giant cell arteriti...
متن کاملTocilizumab, an interleukin-6 inhibitor: a steroid sparing agent in giant cell arteritis.
The Giant Cell Arteritis Actemra (GiACTA) study, the largest randomised trial for this disease to date, involved 251 patients and describes the benefits of tocilizumab, an interleukin-6 inhibitor.1 Patients were randomised to one of 4 groups, in a ratio of 2:1:1:1, to receive: subcutaneous tocilizumab 162 mg weekly (100 patients); or every 2 weeks (50 patients); or placebo (one arm of 50 patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis & Rheumatology
سال: 2019
ISSN: 2326-5191,2326-5205
DOI: 10.1002/art.40876